A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud's.

What Was Tested

The paper reports a study of Angiotensin II in the context of raynaud's, published as a randomized controlled trial.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, women only.

Twelve female patients with SSc (median age 58.5 years, median duration of RP 19.0 years) attended on four occasions: screening, treatment visits 1 and 2 (separated by 3-7 days) and follow-up.

Forty min after each treatment, each patient underwent a standard hand cold challenge.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.

Neither the participants nor the staff measuring them knew who was on Angiotensin II, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Angiotensin II could be set against what happens without it.

In the crossover set-up each of the participants took both Angiotensin II and the comparison in turn, acting as their own control.

The primary end point was the area under the curve (AUC) for rewarming for each finger (eight fingers) over 15 min.

Secondary end points included the maximum finger temperature after rewarming (MAX).

Statistical analyses were performed by multiplicative ANCOVA models.

What Was Measured

The subject headings attached to it are Receptor, Angiotensin, Type 2, Scleroderma, Systemic, Fingers, Body Temperature, Raynaud Disease, Imidazoles and Sulfonamides.

Author keywords: RP, SSc, angiotensin II type 2 receptor agonist, randomized controlled trial and thermography.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in people with raynaud's.

Results are reported in around 2 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Rheumatology (Oxford, England)), a journal based in England.

More context: the Angiotensin II compound page, Raynaud's research.